about
Structural basis for potency differences between GDF8 and GDF11.Loss of betaglycan contributes to the malignant properties of human granulosa tumor cells.Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex.Inhibin binding sites and proteins in pituitary, gonadal, adrenal and bone cells.Germline mutations of inhibins in early-onset ovarian epithelial tumors.Development of novel activin-targeted therapeutics.Cumulin, an Oocyte-secreted Heterodimer of the Transforming Growth Factor-β Family, Is a Potent Activator of Granulosa Cells and Improves Oocyte QualityLentiviral transduction of rat Sertoli cells as a means to modify gene expression.HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors.The bone morphogenetic protein axis is a positive regulator of skeletal muscle mass.The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.The TGF-β Signalling Network in Muscle Development, Adaptation and Disease.Elevated expression of activins promotes muscle wasting and cachexia.Inhibin B is a more potent suppressor of rat follicle-stimulating hormone release than inhibin a in vitro and in vivo.Functional analysis of the human inhibin alpha subunit variant A257T and its potential role in premature ovarian failure.Specific targeting of TGF-β family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease.Identification of distinct inhibin and transforming growth factor beta-binding sites on betaglycan: functional separation of betaglycan co-receptor actions.Activin-A binds follistatin and type II receptors through overlapping binding sites: generation of mutants with isolated binding activities.Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia.A common biosynthetic pathway governs the dimerization and secretion of inhibin and related transforming growth factor beta (TGFbeta) ligandsGeneration of a specific activin antagonist by modification of the activin A propeptide.Growth differentiation factor 9:bone morphogenetic protein 15 (GDF9:BMP15) synergism and protein heterodimerization.Interleukin 11 and activin A synergise to regulate progesterone-induced but not cAMP-induced decidualization.Aberrant GDF9 expression and activation are associated with common human ovarian disorders.The activin A antagonist follistatin inhibits asthmatic airway remodelling.Activation of latent human GDF9 by a single residue change (Gly 391 Arg) in the mature domain.Extra-ovarian expression and activity of growth differentiation factor 9.Species differences in the expression and activity of bone morphogenetic protein 15.Activins and inhibins and their signaling.Identification of protein binding partners of ALK-5 kinase inhibitors.Use of detergent-based buffers allows detection of precursor inhibin forms in an immunoassay format.Molecular characterization of latent GDF8 reveals mechanisms of activation.BMP15 Mutations Associated With Primary Ovarian Insufficiency Reduce Expression, Activity, or Synergy With GDF9.Selection of internal control genes for analysis of gene expression in normal and diseased human dermal fibroblasts using quantitative real-time PCR.2-Phenyl and 2-heterocyclic-4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridines as inhibitors of TGF-β1 and activin A signalling.Retinoic acid promotes Sertoli cell differentiation and antagonises activin-induced proliferation.Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling.Biological activity and in vivo half-life of pro-activin A in male rats.Immunodetection of the murine chemotactic protein CP-10 in bleomycin-induced pulmonary injury.
P50
Q31813087-5339FF40-8BBE-4DA3-8DAC-4DDC0885E950Q33642461-47F6166B-0352-4098-AF4C-7D69E78ED9F7Q33883297-5EC6C578-C616-4D16-A7DC-563275AF630DQ34307667-6C2D620E-9875-451E-BB49-FB88CCC99BE9Q34823160-8A6C2340-8364-4926-9EBF-E62F530C6E0AQ35153096-EFF0600E-D4B6-4AB0-A772-A9E6C8B1F2C0Q36093011-190D80BC-BD29-43EB-AD75-21A7C14FF3F9Q36465183-7C46B403-8C7E-485F-8EFC-B9E05D107D22Q36609892-4B7553B1-332B-4E49-A3FD-CEC3512D0F43Q37267961-34955BCC-C333-4989-B5C1-0B71C5F03AEEQ37745788-46A6CCDE-5AE2-44EC-AB42-26EA6BDC87B7Q38784881-7C86B943-BA1A-46AD-A263-D278741E1185Q39038278-A2525D92-6551-4B6E-A4FB-D8E045EA8F28Q39826940-7994A327-2EA8-47FF-A74A-6C99AA39E81FQ40068538-4A59977A-8ADB-4375-A580-06D89B4CF91FQ40162611-AABDE199-3850-4CE6-B131-EA44869B16F0Q40290804-721410DB-031C-4C01-9CD4-870420A1B7B4Q40306791-EE2966F5-CE64-4ED6-B039-D9191C690796Q40640594-EF054CF1-D829-4E11-8EFF-3147E38E8835Q40689302-D06C9775-E77C-4803-8D3D-856526E06211Q41991001-9E9D7747-E426-4398-BB74-38A65CDA546BQ42808315-CB31F097-2550-40C3-82E2-D2761BD55F4FQ43117534-EC2802A9-B0A3-4AA6-AAB7-1CEC06BB9FC2Q43194301-A64E0253-F01C-42CC-97B6-55A5006CA27CQ44066256-51801A27-E104-4C95-B11E-3A933C410819Q44300553-692472E8-E5F3-434A-9832-B3964C999CF2Q45195194-E1877512-F862-4DC5-93BF-C639721B10ADQ45977857-42AF8A63-AAFC-4849-9624-C94B7333ADF9Q46317251-7697E7A5-1CBE-456C-85CA-7477BA1D714CQ46346690-3003288B-61F7-4471-B2B8-D8EE9E6DCB7DQ46728589-E8932F7B-305F-434C-A0E3-0FF8C531CFB6Q47868269-7D80FE94-8B8A-4DB0-99A4-6B9367BCC765Q48216682-AD076A86-1B10-4C19-8599-661CB980B50EQ48525242-326EF2FC-EB05-426B-9546-EE80EF83E3B0Q50481455-9921DA07-9186-4D5C-A84B-F589DA4A7029Q50515953-C6831CD2-00FC-4306-9672-177B95888306Q50854415-7E5D57DC-352B-42E9-B963-3B17940177B0Q50933544-121778B4-E205-418A-8320-5F3D9A079392Q51599604-8201A6A0-457A-4645-B373-1C48F1DAD8E4Q54142570-223DB3D8-9E2F-41CE-AE20-22E89CF89B6E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Craig A Harrison
@ast
Craig A Harrison
@en
Craig A Harrison
@es
Craig A Harrison
@nl
type
label
Craig A Harrison
@ast
Craig A Harrison
@en
Craig A Harrison
@es
Craig A Harrison
@nl
prefLabel
Craig A Harrison
@ast
Craig A Harrison
@en
Craig A Harrison
@es
Craig A Harrison
@nl
P106
P31
P496
0000-0003-1059-3682